Mirtazapin Actavis (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Actavis, is a tetracyclic antidepressant presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients. GNH USA supplies Mirtazapin Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is a tetracyclic antidepressant that acts on central neurotransmitter pathways to alleviate depressive conditions. - Major depressive disorder: reduces depressive symptoms and improves functional outcomes in adults. - Bipolar depressive episodes (adjunct): helps manage depressive phases when used alongside mood stabilisers. - Depression‑related anxiety: alleviates anxiety symptoms that accompany depressive states.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Suicidal thoughts or behaviour - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Hepatic dysfunction - Significant QT prolongation

Before initiating therapy, clinicians should consider several safety aspects. - Hepatic function: assess liver enzymes in patients with hepatic impairment. - Weight monitoring: counsel patients about potential weight gain. - Elderly patients: use caution due to increased risk of sedation and falls. - Discontinuation: avoid abrupt cessation to reduce withdrawal symptoms. - Suicidal ideation: monitor for emergence of suicidal thoughts, especially early in treatment. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may precipitate hypertensive crisis. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): risk of serotonin syndrome. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce mirtazapine exposure and efficacy.